Ocrevus and Tysabri appear to work equally well to control relapsing MS
Danish study finds no difference in relapse rates or disease progression Written by Margarida Maia, PhD | February 26, 2026 Ocrevus and Tysabri…
Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS 02/17/26 Roche has reported late-breaking phase 3 data…
Stuart Schlossman
Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis
ORIGINAL RESEARCH article Front. Neurol., 29 January 2026 – Sec. Multiple Sclerosis and Neuroimmunology Volume 17 – 2026 | https://doi.org/10.3389/fneur.2026.1738815 Abstract…
Stuart Schlossman
REFRAMING MS
AN RMS TREATMENT ON YOUR TERMS Why Choose Kesimpta for an MS Therapy? KESIMPTA® is the only B-cell treatment you…
Stuart Schlossman
Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.
More than 2 years after its original approval, Sandoz’ natalizumab (Tyruko) biosimilar is officially available to patients with multiple sclerosis…
Stuart Schlossman
Do you Know about the 2-TIMES-A-YEAR* OCREVUS and its AVAILABILITY for treating RMS and PPMS TWO different ways?
As a ~10-minute† subcutaneous injection OR as a 4-hour†/2-hour†‡ intravenous infusion To Learn More, click here: www.ocrevus.com…
Stuart Schlossman
Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
February 7, 2026 – Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of…
Stuart Schlossman
New biomarker may help identify MS patients for BTK inhibitors
Balance between 2 molecules seen as inflammation marker Written by Marisa Wexler, MS | January 7, 2026 The balance between two immune signaling…
Stuart Schlossman
BTK inhibitors match Aubagio at reducing relapse rates in MS: Review
Further studies needed to determine if they provide lasting benefits Written by Margarida Maia, PhD | February 3, 2026 Experimental Bruton’s tyrosine kinase…
Stuart Schlossman
Immune Signal Ratio May Predict Progressive Multiple Sclerosis
January 2, 2026 Summary: A long-term study has identified a potential biomarker that could help detect which patients are progressing toward…
Stuart Schlossman
